

Supplemental Table 3. Specific cancer diagnosis related to death according to baseline albuminuria

Cancer-specific mortality	eGFR (mL/min/1.73 m ²)	No. of specific cancers	No. of events	Incidence rate (/1,000 PY)	Univariable model		Multivariable model ^a	
					HR (95% CI)	p-value	HR (95% CI)	p-value
Oral cancer	Negative, trace	9,667,046	2,298	0.023	1.00 (Reference)		1.00 (Reference)	
	1+	169,069	77	0.046	1.98 (1.57–2.48)	<0.001	1.39 (1.11–1.75)	0.005
	2+	62,608	27	0.045	1.92 (1.31–2.80)	0.001	1.20 (0.82–1.76)	0.34
	3, 4+	19,115	11	0.061	2.66 (1.47–4.82)	0.001	1.51 (0.84–2.74)	0.17
Esophagus cancer	Negative, trace	9,667,046	3,373	0.034	1.00 (Reference)		1.00 (Reference)	
	1+	169,069	106	0.063	1.85 (1.52–2.24)	<0.001	1.19 (0.98–1.45)	0.08
	2+	62,608	53	0.087	2.56 (1.95–3.35)	<0.001	1.45 (1.11–1.91)	0.007
	3, 4+	19,115	15	0.084	2.46 (1.48–4.08)	<0.001	1.28 (0.77–2.12)	0.35
Stomach cancer	Negative, trace	9,667,046	18,035	0.184	1.00 (Reference)		1.00 (Reference)	
	1+	169,069	556	0.332	1.81 (1.66–1.97)	<0.001	1.29 (1.18–1.40)	<0.001
	2+	62,608	233	0.384	2.10 (1.84–2.39)	<0.001	1.33 (1.17–1.52)	<0.001
	3, 4+	19,115	79	0.441	2.42 (1.94–3.02)	<0.001	1.41 (1.13–1.76)	<0.001
Colorectal cancer	Negative, trace	9,667,046	16,302	0.166	1.00 (Reference)		1.00 (Reference)	
	1+	169,069	503	0.301	1.82 (1.66–1.99)	<0.001	1.20 (1.10–1.31)	<0.001
	2+	62,608	226	0.373	2.26 (1.98–2.58)	<0.001	1.31 (1.14–1.49)	<0.001
	3, 4+	19,115	84	0.469	2.86 (2.31–3.55)	<0.001	1.49 (1.20–1.85)	0.0003
Liver cancer	Negative, trace	9,667,046	25,083	0.255	1.00 (Reference)		1.00 (Reference)	
	1+	169,069	850	0.508	1.99 (1.86–2.13)	<0.001	1.31 (1.22–1.40)	<0.001
	2+	62,608	420	0.693	2.72 (2.47–3.00)	<0.001	1.54 (1.40–1.70)	<0.001
	3, 4+	19,115	160	0.894	3.53 (3.03–4.13)	<0.001	1.83 (1.57–2.14)	<0.001
Biliary cancer	Negative, trace	9,667,046	10,397	0.106	1.00 (Reference)		1.00 (Reference)	
	1+	169,069	290	0.173	1.64 (1.46–1.85)	<0.001	1.08 (0.96–1.21)	0.21
	2+	62,608	137	0.226	2.15 (1.82–2.55)	<0.001	1.24 (1.04–1.46)	0.01
	3, 4+	19,115	47	0.263	2.52 (1.89–3.35)	<0.001	1.32 (0.99–1.75)	0.06
Pancreatic cancer	Negative, trace	9,667,046	13,886	0.141	1.00 (Reference)		1.00 (Reference)	
	1+	169,069	453	0.271	1.92 (1.75–2.11)	<0.001	1.23 (1.12–1.35)	<0.001
	2+	62,608	185	0.305	2.18 (1.88–2.52)	<0.001	1.19 (1.03–1.38)	0.02
	3, 4+	19,115	58	0.324	2.33 (1.80–3.01)	<0.001	1.13 (0.87–1.46)	0.37
Laryngeal cancer	Negative, trace	9,667,046	691	0.007	1.00 (Reference)		1.00 (Reference)	
	1+	169,069	20	0.012	1.70 (1.09–2.66)	0.02	1.04 (0.67–1.63)	0.85
	2+	62,608	11	0.018	2.59 (1.43–4.71)	0.002	1.37 (0.75–2.49)	0.31
	3, 4+	19,115	4	0.022	3.21 (1.20–8.58)	0.02	1.49 (0.55–3.98)	0.43
Lung cancer	Negative, trace	9,667,046	42,917	0.437	1.00 (Reference)		1.00 (Reference)	
	1+	169,069	1,264	0.755	1.73 (1.64–1.83)	<0.001	1.16 (1.10–1.23)	<0.001
	2+	62,608	588	0.970	2.23 (2.06–2.42)	<0.001	1.32 (1.22–1.43)	<0.001
	3, 4+	19,115	191	1.067	2.47 (2.14–2.85)	<0.001	1.31 (1.14–1.51)	<0.001
Skin cancer	Negative, trace	9,667,046	646	0.007	1.00 (Reference)		1.00 (Reference)	
	1+	169,069	13	0.008	1.19 (0.68–2.05)	0.54	0.86 (0.50–1.50)	0.60
	2+	62,608	7	0.012	1.77 (0.84–3.72)	0.13	1.15 (0.54–2.42)	0.72
	3, 4+	19,115	1	0.006	0.86 (0.12–6.11)	0.88	0.51 (0.07–3.60)	0.50
Renal cancer	Negative, trace	9,667,046	1,979	0.020	1.00 (Reference)		1.00 (Reference)	
	1+	169,069	82	0.049	2.44 (1.96–3.04)	<0.001	1.49 (1.20–1.87)	<0.001
	2+	62,608	52	0.086	4.28 (3.25–5.64)	<0.001	2.17 (1.64–2.87)	<0.001
	3, 4+	19,115	21	0.117	5.88 (3.83–9.04)	<0.001	2.55 (1.66–3.94)	<0.001
Bladder cancer	Negative, trace	9,667,046	2,577	0.026	1.00 (Reference)		1.00 (Reference)	
	1+	169,069	151	0.090	3.46 (2.94–4.08)	<0.001	2.16 (1.83–2.60)	<0.001
	2+	62,608	79	0.130	5.02 (4.01–6.27)	<0.001	2.72 (2.17–3.41)	<0.001
	3, 4+	19,115	29	0.162	6.29 (4.36–9.07)	<0.001	3.04 (2.10–4.39)	<0.001

(Continued on the next page)

Supplementary Table 3. Continued

Cancer-specific mortality	eGFR (mL/min/1.73 m ²)	No. of specific cancers	No. of events	Incidence rate (/1,000 PY)	Univariable model		Multivariable model ^a	
					HR (95% CI)	p-value	HR (95% CI)	p-value
Nerves cancer	Negative, trace	9,667,046	2,948	0.030	1.00 (Reference)		1.00 (Reference)	
	1+	169,069	58	0.035	1.16 (0.89–1.50)	0.26	0.92 (0.71–1.19)	0.52
	2+	62,608	29	0.048	1.61 (1.11–2.32)	0.01	1.17 (0.81–1.69)	0.40
	3, 4+	19,115	7	0.039	1.32 (0.63–2.77)	0.46	0.90 (0.43–1.88)	0.77
Thyroid cancer	Negative, trace	9,667,046	710	0.007	1.00 (Reference)		1.00 (Reference)	
	1+	169,069	30	0.018	2.49 (1.73–3.59)	<0.001	1.72 (1.19–2.49)	0.004
	2+	62,608	7	0.012	1.61 (0.76–3.38)	0.21	1.00 (0.47–2.11)	>0.99
	3, 4+	19,115	3	0.017	2.34 (0.75–7.28)	0.14	1.37 (0.44–4.26)	0.59
Lymphoma cancer	Negative, trace	9,667,046	4,249	0.043	1.00 (Reference)		1.00 (Reference)	
	1+	169,069	136	0.081	1.89 (1.59–2.24)	<0.001	1.36 (1.14–1.61)	<0.001
	2+	62,608	57	0.094	2.19 (1.69–2.85)	<0.001	1.41 (1.08–1.83)	0.01
	3, 4+	19,115	21	0.117	2.76 (1.80–4.23)	<0.001	1.64 (1.06–2.52)	0.02
Multimyeloma cancer	Negative, trace	9,667,046	2,173	0.022	1.00 (Reference)		1.00 (Reference)	
	1+	169,069	114	0.068	3.09 (2.56–3.73)	<0.001	2.25 (1.86–2.72)	<0.001
	2+	62,608	53	0.087	3.98 (3.03–5.23)	<0.001	2.60 (1.98–3.42)	<0.001
	3, 4+	19,115	31	0.173	7.95 (5.58–11.33)	<0.001	4.88 (3.41–6.97)	<0.001
Leukemia cancer	Negative, trace	9,667,046	4,127	0.042	1.00 (Reference)		1.00 (Reference)	
	1+	169,069	113	0.068	1.61 (1.34–1.94)	<0.001	1.22 (1.02–1.48)	0.03
	2+	62,608	45	0.074	1.78 (1.32–2.38)	<0.001	1.22 (0.91–1.64)	0.19
	3, 4+	19,115	11	0.061	1.48 (0.82–2.67)	0.20	0.95 (0.53–1.73)	0.88
Breast cancer	Negative, trace	4,383,967	3,472	0.077	1.00 (Reference)		1.00 (Reference)	
	1+	77,470	77	0.099	1.28 (1.02–1.61)	0.03	1.15 (0.92–1.45)	0.22
	2+	27,547	24	0.088	1.14 (0.76–1.70)	0.52	0.97 (0.63–1.45)	0.87
	3, 4+	8,136	6	0.076	0.99 (0.45–2.21)	0.98	0.80 (0.36–1.79)	0.59
Cervical cancer	Negative, trace	4,383,967	1,206	0.027	1.00 (Reference)		1.00 (Reference)	
	1+	77,470	37	0.048	1.77 (1.28–2.46)	<0.001	1.50 (1.08–2.08)	0.02
	2+	27,547	22	0.080	3.00 (1.97–4.58)	<0.001	2.36 (1.54–3.60)	<0.001
	3, 4+	8,136	3	0.038	1.42 (0.46–4.41)	0.54	1.06 (0.34–3.30)	0.92
Corpus cancer	Negative, trace	4,383,967	735	0.016	1.00 (Reference)		1.00 (Reference)	
	1+	77,470	17	0.022	1.34 (0.83–2.16)	0.24	1.10 (0.68–1.78)	0.70
	2+	27,547	5	0.018	1.12 (0.47–2.70)	0.80	0.83 (0.34–2.00)	0.68
	3, 4+	8,136	2	0.025	1.57 (0.39–6.25)	0.52	1.07 (0.27–4.30)	0.92
Ovarian cancer	Negative, trace	4,383,967	2,135	0.048	1.00 (Reference)		1.00 (Reference)	
	1+	77,470	41	0.053	1.11 (0.81–1.51)	0.51	0.95 (0.70–1.30)	0.77
	2+	27,547	14	0.051	1.08 (0.64–1.83)	0.77	0.87 (0.51–1.47)	0.59
	3, 4+	8,136	6	0.076	1.61 (0.72–3.59)	0.24	1.23 (0.55–2.75)	0.61
Prostate cancer	Negative, trace	5,283,079	3,909	0.073	1.00 (Reference)		1.00 (Reference)	
	1+	91,599	126	0.141	1.94 (1.62–2.31)	<0.001	1.15 (0.96–1.38)	0.12
	2+	35,061	57	0.171	2.37 (1.82–3.08)	<0.001	1.23 (0.95–1.60)	0.12
	3, 4+	10,979	30	0.300	4.20 (2.93–6.01)	<0.001	1.98 (1.38–2.84)	<0.001
Testicular cancer	Negative, trace	5,283,079	25	0.000	NA	NA	NA	NA
	1+	91,599	0	NA	NA	NA	NA	NA
	2+	35,061	0	NA	NA	NA	NA	NA
	3, 4+	10,979	0	NA	NA	NA	NA	NA

CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; NA, not applicable; PY, person-year.

^aThe multivariable model was adjusted for age, sex, smoking, alcohol consumption, regular physical activity, history of diabetes mellitus, hypertension, dyslipidemia, presence of dipstick albuminuria, body mass index, systolic blood pressure, fasting glucose, and total cholesterol.